PanTera and TerraPower Isotopes join forces to accelerate access to actinium-225

Under this collaboration, both companies will use TerraPower Isotope’s natural decay method based on thorium-229 (²²⁹Th) and PanTera’s “Gamma route” based on the Rhodotron® and radium-226 to produce ²²⁵Ac.

²²⁵Ac is a promising alpha emitter for use in Targeted Alpha Therapy (TAT). A series of molecules that are currently under research, combined with ²²⁵Ac through further manufacturing, have the potential to treat a variety of cancers, targeting solid tumors, metastases, and systemic cancers such as leukemia. There are several clinical studies currently in progress, ranging from preclinical development through to phase 3 clinical trials. Whilst there is high demand, there is a scarcity of ²²⁵Ac. The collaboration between PanTera and TerraPower Isotopes is seeking to address this supply issue and support the clinical development of ²²⁵Ac based drugs as a potential treatment option for cancer.

Scott Claunch, President of TerraPower Isotopes, added: “Consistent with TerraPower’s vision of developing innovative solutions to help fight disease using nuclear science, TerraPower Isotopes is thrilled to secure this collaboration with PanTera. Demand for ²²⁵Ac is expected to increase as more radiopharmaceutical treatments using ²²⁵Ac are developed to treat a variety of different types of cancers. This collaboration will help us supply this valuable material to the pharmaceutical industry and meet the growing global demand.” 

^{[1] TerraPower Isotopes produced Actinium-225 is intended to be used as starting material for further manufacturing processes and, as starting material, is not manufactured in accordance with current good manufacturing practices.}